EC Number   |
Application |
Reference |
|---|
   2.4.1.212 | analysis |
a rapid, continuous, and convenient three-enzyme coupled UV absorption assay is developed to quantitate the glucuronic acid and N-acetylglucosamine transferase activities of hyaluronan synthase. Activity is measured by coupling the UDP produced from the PmHAS-catalyzed transfer of UDP-GlcNAc and UDP-GlcUA to a hyaluronic acid tetrasaccharide primer with the oxidation of NADH. Using a fluorescently labeled primer, the products are characterized by gel electrophoresis. The assay can be used to determine kinetic parameters, inhibition constants, and mechanistic aspects of this enzyme. In addition, it can be used to quantify PmHAS during purification of the enzyme from culture media |
671308 |
| 2.4.1.212 | analysis |
quantification of newly synthesized hyaluronan by polyacrylamide gel electrophoresis of fluorophore-labeled saccharides and high performance liquid chromatography. The method measures HAS activity in the plasma membrane fraction and also in the cytosolic membranes. The technique is used to evaluate the effects of 4-methylumbeliferone, phorbol 12-myristate 13-acetate, interleukin 1, platelet-derived growth factor BB, and tunicamycin on HAS activities |
704558 |
| 2.4.1.212 | biotechnology |
optimization of the recombinant enzyme expression in Escherichia coli for large scale production of hyaluronan polymers for usage in basic studies, and for biotechnological creation of functional carbohydrates in medical purposes, engineering of produced product chain length |
659346 |
| 2.4.1.212 | drug development |
inhibition of hyaluronan synthase 3-dependent synthesis of hyaluronan dampens systemic Th1 cell polarization and reduces plaque inflammation. Hyaluronan synthase 3 might be a promising therapeutic target in atherosclerosis. Because hyaluronan synthase 3 is regulated by IL-1beta, therapeutic anti-IL-1beta antibodies, may exert their beneficial effects on inflammation in post-myocardial infarction patients in part via effects on hyaluronan synthase 3 |
759705 |
| 2.4.1.212 | drug development |
the enzyme actively synthesizes hyaluronan in hepatic stellate cells and promotes hepatic stellate cells activation and liver fibrosis through Notch1. Targeted hyaluronan inhibition may have potential to be an effective therapy for liver fibrosis |
760190 |
| 2.4.1.212 | medicine |
an in vitro model is developed to study the biomechanical effects of excess hyaluronan, which is relevant to many cardiovascular events |
691192 |
| 2.4.1.212 | medicine |
expression of HAS1Vb, an intronic splice variant, correlates with poor survival in multiple myeloma patients |
672775 |
| 2.4.1.212 | medicine |
HAS 2 appears to be a major contributor to the baseline levels of hyaluronan. Reduced HAS 2 gene expression and increased excreted urinary hyaluronidase activity during dehydration contribute to the reduced amount of hyaluronan and to antidiuretic response. In hydrated animals, the diuretic response is followed by a 58% elevation in papillary hyaluronan and a 45% reduction in the excreted urinary hyaluronidase activity. No difference is determined in HAS 13 mRNA or HYAL 1, 34 mRNA expression. In dehydrated animals, antidiuresis is followed by a 22% reduction in papillary hyaluronan and a 62% elevation in excreted urinary hyaluronidase activity. Plasma vasopressin is 2.8-fold higher in dehydrated versus hydrated rats |
705486 |
| 2.4.1.212 | medicine |
HAS1 variant Vc is transforming in vitro and tumorigenic in vivo when introduced as a single oncogene to untransformed cells. In co-transfected cells, full length HAS1 and HAS1 variants interact with themselves and with each other to form heteromeric multiprotein assemblies |
704503 |
| 2.4.1.212 | medicine |
heregulin activation of ErbB2-ERK signaling modulates HAS phosphorylation/activation and hyaluronan production leading to CD-44-mediated oncogenic events and ovarian cancer progression |
692996 |
